INTRODUCTION
============

β-Catenin is an important co-activator downstream of the oncogenic Wnt signaling pathway, so mutations in the β-catenin gene (*CTNNB1*) have been implicated in oncogenesis ([@b35-molce-42-1-8]; [@b48-molce-42-1-8]; [@b57-molce-42-1-8]). Recently, large-scale cancer databases, such as The Cancer Genome Atlas (TCGA) pan-cancer analysis project, have leveraged systemic analyses on genome, exome, and transcriptome data from all types of cancers ([@b4-molce-42-1-8]; [@b28-molce-42-1-8]; [@b67-molce-42-1-8]). Multidimensional cancer genome data are available on cBioPortal, an open platform for cancer genome analysis and visualization ([@b10-molce-42-1-8]; [@b16-molce-42-1-8]). In this review, we have employed pan-cancer genome databases to analyze the current status of β-catenin gene (*CTNNB1*) mutations to identify mutation hotspots and to re-evaluate the oncogenic roles of specific β-catenin mutant proteins. An extensive review on the clinical aspects of the β-catenin protein is beyond the scope of this mini review, so we have provided a brief introduction regarding the basic biology of the β-catenin protein.

A BRIEF INTRODUCTION TO THE β-CATENIN PROTEIN
=============================================

β-Catenin is a multitasking protein involved in transcription and cell adhesion ([@b27-molce-42-1-8]; [@b38-molce-42-1-8]; [@b68-molce-42-1-8]). In particular, β-catenin is an important co-activator of Wnt target genes, such as *cyclin D1* and *c-myc* ([@b35-molce-42-1-8]; [@b48-molce-42-1-8]). However, in differentiated cells, where Wnt signaling is off, the central regulatory mechanism for β-catenin is sequential phosphorylation in the N-terminal region followed by ubiquitin-mediated proteolysis ([Fig. 1A](#f1-molce-42-1-8){ref-type="fig"}). Casein Kinase-1α phosphorylates the S45 residue and primes subsequent phosphorylation on T41/S37/S33 by GSK-3β, leading to the binding of ubiquitin E3 ligase β-transducin repeats-containing proteins (β-TrCP) at the N-terminal region (D32 to S37) in a phosphorylation-dependent manner ([@b25-molce-42-1-8]; [@b43-molce-42-1-8]). Specific phosphorylation and ubiquitination occur in the APC/Axin complex, termed as the β-catenin destruction complex ([@b65-molce-42-1-8]). In contrast, the destruction complex functions no more, so the level of the β-catenin protein in the cytoplasm increases following Wnt activation ([Fig. 1B](#f1-molce-42-1-8){ref-type="fig"}). The mechanism by which Wnt signaling stabilizes β-catenin needs to be better understood in the aspect of the β-catenin destruction complex ([@b34-molce-42-1-8]; [@b30-molce-42-1-8]; [@b42-molce-42-1-8]; [@b66-molce-42-1-8]). Finally, Wnt-stimulated β-catenin is translocated into the nucleus, where it acts as transcriptional co-activator with DNA binding TCF/LEF proteins and activates many developmentally important, cancer-related and pathogenic genes ([@b52-molce-42-1-8]).

FREQUENCY OF GENOMIC ALTERATIONS IN THE *CTNNB1* GENE IN CANCERS
================================================================

Small-scale targeted gene analysis demonstrates mutations in the β-catenin gene (*CTNNB1* ) in some cancers ([@b55-molce-42-1-8]; [@b57-molce-42-1-8]). Large-scale β-catenin mutational landscape was revealed from clinical sequencing of 10,000 prospective cancer patients by the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) ([@b74-molce-42-1-8]). [Figure 2](#f2-molce-42-1-8){ref-type="fig"} shows the frequency of *CTNNB1* alterations across tumor types. A high frequency of *CTNNB1* mutations are found in endometrial (16%), hepatobiliary (12%), melanoma (7%), and colorectal (6%) cancers. It is noteworthy that the frequency of *APC* mutations is much higher (approximately 70%) than that of *CTNNB1* in colorectal cancer, but *CTNNB1* and *APC* mutations exist in the exclusive manner. The alteration frequency of *CTNNB1* in endometrial, liver, and colorectal cancer from other genomic analysis networks is compiled in [Table 1](#t1-molce-42-1-8){ref-type="table"}. In addition, cancer cell lines with mutations in *CTNNB1* are summarized in [Table 2](#t2-molce-42-1-8){ref-type="table"}.

Endometrial cancer
------------------

Wnt/β-catenin pathway has been linked to endometrial cancer. Loss of APC function in the mouse endometrium induces nuclear β-catenin accumulation in uterine hyperplasia and squamous cell metaplasia. Although APC loss alone does not lead to malignant transformation, APC loss enhances endometrial tumorigenesis driven by PTEN loss ([@b69-molce-42-1-8]). The majority of *CTNNB1* alterations occur in endometrial carcinoma, but not in carcinosarcoma or clear cell carcinoma as indicated in [Table 1](#t1-molce-42-1-8){ref-type="table"} ([@b8-molce-42-1-8]; [@b9-molce-42-1-8]; [@b40-molce-42-1-8]; [@b64-molce-42-1-8]). In endometrial cancer cases from TCGA, the alterations of *CTNNB1* or *APC* genes are 30% or 12% of 240 patients, respectively ([@b8-molce-42-1-8]). Loss of APC function arises from truncation of the gene, but the frequency is only 6% in endometrial cancer. Thus, in endometrial cancer, *CTNNB1* mutations, rather than *APC* mutations, might be direct driver mutations. Recently, 245 endometrial cancer patient samples were sequenced using 46--200 gene panels. *CTNNB1* mutations appear more frequently in low-grade (grades 1--2) and early-stage (stages I--II) patients. More significantly, the patients harboring *CTNNB1* mutations are associated with worse recurrence-free survival ([@b39-molce-42-1-8]).

Hepatocellular carcinoma (HCC)
------------------------------

Liver cancer is the seventh most common cancer and the fourth leading cause of cancer mortality worldwide ([@b5-molce-42-1-8]). However, treatment options are still limited for patients with advanced HCC due to the heterogeneity of genome alterations. Genome-wide studies have been carried out to identify driver genes responsible for tumorigenesis. SNP array analysis of 125 HCC cases have identified that four genes (*CTNNB1* (32.8%), *TP53* (20.8%), *ARID1A* (16.8%), and *AXIN1* (15.2%)) are altered in more than 10% of the samples ([@b21-molce-42-1-8]). Whole exome sequencing analysis with 231 early-stage HCC Korean patient samples identified recurrent somatic mutations in *CTNNB1* (23%) and *TP53* (32%) ([@b3-molce-42-1-8]). In addition, *CTNNB1* and *TP53* were found to be frequently altered in a large cohort of HCC patient samples ([@b9-molce-42-1-8]; [@b15-molce-42-1-8]; [@b61-molce-42-1-8]). The *CTNNB1* gene is also frequently altered in hepatocellular adenoma (HCA) ([@b54-molce-42-1-8]). β-catenin transgenic mouse models have been used to define a function of β-catenin in HCC tumorigenesis ([@b50-molce-42-1-8]). Ectopic expression of either wild-type or mutant β-catenin is not sufficient to induce tumorigenesis ([@b23-molce-42-1-8]; [@b51-molce-42-1-8]). In some cases, β-catenin may accelerate tumorigenesis in cooperating with activated Ha-Ras ([@b24-molce-42-1-8]) or heterozygote deleted *Lkb1* ([@b47-molce-42-1-8]).

Colorectal cancer (CRC)
-----------------------

Wnt/β-cat signaling plays an important role in the tumorigenesis of CRC ([@b57-molce-42-1-8]). In particular, alteration of *APC*, a negative regulator in Wnt signaling, is found in approximately 70% of CRC patients. Most *APC* alterations are truncation mutations, which cannot facilitate the proteolysis of β-catenin. In addition, loss of heterozygosity is frequently found in colorectal cancers. As shown in [Table 1](#t1-molce-42-1-8){ref-type="table"}, genetic alterations also occurred in the *CTNNB1* gene (5% of TCGA, 5% of DFCI, 6.9% of Genentech) ([@b17-molce-42-1-8]; [@b62-molce-42-1-8]). Several studies reported that β-catenin has oncogenic activity in CRC cells, so the inhibition of β-catenin by gene targeting or knockdown resulted in growth inhibition of colorectal cancer cells ([@b7-molce-42-1-8]; [@b20-molce-42-1-8]; [@b32-molce-42-1-8]; [@b59-molce-42-1-8]).

MUTATION HOTSPOTS IN EXON 3 (ENCODING THE N-TERMINAL REGION) OF THE β-CATENIN GENE
==================================================================================

The β-catenin protein is composed of three domains: an N-terminal domain (\~130 aa), a central domain (residue 141-664) made of 12 Armadillo (Arm) repeats and a C-terminal domain (\~100 aa) ([Fig. 3A](#f3-molce-42-1-8){ref-type="fig"}). The central domain of the protein, the Arm repeats domain, forms a rigid rod-like structure and interacts with many binding proteins ([@b72-molce-42-1-8]). However, it has been difficult to determine the structure of the terminal regions (N- and C-terminals) of β-catenin, so they are likely to be flexible and could be intrinsically disordered ([@b71-molce-42-1-8]). Interestingly, the N-terminal region of the β-catenin protein is encoded by exon 3 (amino acid residues 5--80) of *CTNNB1*, so the N-terminal mutations can also be referred to as exon 3 mutations. *CTNNB1* mutation hotspots were statistically analyzed by the Sorting Intolerant From Tolerant (SIFT) and the Polymorphism Phenotyping (PolyPhen) ([@b2-molce-42-1-8]; [@b49-molce-42-1-8]; [@b63-molce-42-1-8]).

Missense mutations affecting the N-terminal region of the β-catenin protein
---------------------------------------------------------------------------

In most cancers, mutations are found in the N-terminal region of β-catenin, especially in exon 3 of β-catenin mRNA ([Fig. 3B](#f3-molce-42-1-8){ref-type="fig"}). In endometrial cancers, integrated analysis showed that exon 3 mutations in β-catenin mRNA are associated with an aggressive phenotype of low-grade and low-stage in younger women ([@b44-molce-42-1-8]). These studies suggest that β-catenin mutations can be a prognostic marker for aggressive endometrial cancer. Additionally, in liver cancer, hotspot mutations in *CTNNB1* were deeply analyzed in a large cohort of patients from HCA to carcinoma (HCC). S45, K335, and N387 mutations result in weak activation of β-catenin and are frequently found in HCA. T41 mutations show relatively moderate activation. Exon 3 deletion and β-TrCP binding site (D32-S37) mutations show strong activation and are enriched in HCA/HCC borderline and HCC, respectively. Highly activated β-catenin is associated with malignant tumors, as evaluated by glutamine synthase staining. Although S45 mutations show weak activation, most S45 mutant alleles in HCC are duplicated, resulting in strong activation of β-catenin. This study suggests that HCA harboring high/moderate mutants or S45 mutants may be associated with malignant transformation ([@b58-molce-42-1-8]). Accelerated liver regeneration and hepatocarcinogenesis was also observed in mouse overexpressing S45 mutant β-catenin ([@b51-molce-42-1-8]). In colorectal cancers, most somatic mutations are observed at D32, S33, G34, S37, T41, and S45 in exon 3 of β-catenin mRNA. These hotspot mutations have been shown to stabilize β-catenin by disturbing the phosphorylation-dependent ubiquitination, leading to tumorigenesis. S45 is a priming-phosphorylation site for Casein Kinase I alpha (CK1α) ([@b43-molce-42-1-8]). S33, S37, and T41 are further phosphorylated by GSK3β. D32 and G34 is required to bind with β-TrCP, a component of ubiquitin E3 ligase for phosphorylated β-catenin ([@b1-molce-42-1-8]; [@b25-molce-42-1-8]).

Exon 3-spanning in-frame deletion in metastatic colorectal cancers
------------------------------------------------------------------

Recently, prospective targeted sequencing was reported with metastatic and early-stage colorectal cancer patients of a large cohort study ([@b73-molce-42-1-8]). In this MSK study, the frequency of *CTNNB1* alterations (8%) is slightly higher than that in TCGA cohort (5% of TCGA pan-cancer atlas), but in-frame deletion is highly enriched in the MSK cohort. This difference may be due to the distinct features between MSK and TCGA cohorts. The MSK cohort includes 47% of metastases that were not included in TCGA cohort, representing more aggressive and advanced disease. Activating hotspot mutations of β-catenin are more frequently occurred in microsatellite instability-high (MSI-H) tumors than in microsatellite stable (MSS) tumors (25% of MSI-H, 6% of MSS). Interestingly, however, exon 3-spanning in-frame deletions were identified only in MSS tumors and the nuclear staining of β-catenin was observed in tumors harboring inframe deletions in *CTNNB1* ([@b73-molce-42-1-8]).

CONCLUSION
==========

Large-scale analysis of pan-cancer genomic database revealed a high frequency of *CTNNB1* mutations in endometrial, liver, and colorectal cancers. In addition, mutations are frequently located near exon 3 of *CTNNB1*, which encode for the regulatory amino acids (D32, S33, G34, S37, T41, and S45) at the N-terminal region of the protein. Since the N-terminal region is highly unstructured and flexible, the contributions of N-terminal hotspot mutations from a structural perspective are not easy to comprehend ([@b13-molce-42-1-8]; [@b18-molce-42-1-8]; [@b71-molce-42-1-8]). Rather, their contribution to cancer development should be understood in terms of their roles in normal and pathogenic epithelial cell states.

FUTURE PERSPECTIVES
===================

Re-evaluating hotspot mutations
-------------------------------

The high frequency of mutations affecting the GSK3β and β-TrCP-binding sites (D32, S33, G34, S37) can be explained by their roles in the β-catenin destruction complex ([@b46-molce-42-1-8]; [@b65-molce-42-1-8]). However, higher frequencies of S45 and T41 mutations cannot be easily explained in terms of the residues for priming and relay kinases, respectively. In fact, recent study suggested the uncoupling of CK1α phosphorylation on S45 residue to GSK3β phosphorylation on S37/S33 residues. The phosphorylations on the T41/S45 residues of β-catenin were spatially uncoupled from the phosphorylated S33/S37/T41 ([@b45-molce-42-1-8]). In addition, a previous study reported that the phosphorylations on S33/S37/T41 can occur in the absence of the phospho-S45 in colon cancer cells ([@b70-molce-42-1-8]). In desmoid-type fibromatosis, protein stability and target genes for the S45F mutant are different from those of the wild-type β-catenin ([@b11-molce-42-1-8]). Moreover, the S45F mutation is associated with low efficacy of a cyclooxygenase-2 inhibitor in desmoid tumors ([@b22-molce-42-1-8]). It will be important to determine the oncogenic role of the S45 mutant β-catenin protein, as a type of mutation distinct from other mutant β-catenin proteins.

β-catenin in multiple protein complexes
---------------------------------------

β-Catenin protein was first discovered as a component of the adherens junction ([@b53-molce-42-1-8]). Later, it is considered as a multitasking protein involved in transcription as well as in cell adhesion ([@b27-molce-42-1-8]; [@b38-molce-42-1-8]; [@b68-molce-42-1-8]). However, it should be noted that most β-catenin proteins reside in the adhesion complex near the plasma membrane in which it interacts with E-cadherin and α-catenin with high affinities ([@b26-molce-42-1-8]). Multiple roles of β-catenin protein may come from multiprotein assembly forming distinct complexes in different intracellular locations ([@b72-molce-42-1-8]). In the nucleus, β-catenin associates with DNA binding proteins, such as TCF/LEF and BCL9 ([@b19-molce-42-1-8]; [@b60-molce-42-1-8]). Collectively, the N-terminal region of β-catenin is critical for regulating the adhesion and transcription functions of the protein. Thus, the regulatory mechanism of phosphorylation may differ in distinct β-catenin complexes ([@b14-molce-42-1-8]). Therefore, many questions arise as to whether the specific mutant β-catenin proteins can form a previously unknown complex, in addition to the adhesion, destruction, and transcription complexes ([Fig. 4](#f4-molce-42-1-8){ref-type="fig"}). We hope that the clinical information gained from the large cancer genome databases could facilitate the study of novel functions of β-catenin in RNA metabolism as an RNA-binding protein ([@b27-molce-42-1-8]; [@b33-molce-42-1-8]; [@b31-molce-42-1-8]; [@b41-molce-42-1-8]). To enhance our understanding of such novel functions, a systematic mutant β-catenin library could be developed to link the differential functional impacts to specific mutations in cancer. More functional studies on specific mutant β-catenin proteins will open up new avenues for elucidating the mechanisms underlying mutant β-catenin-mediated oncogenesis.

Novel therapeutic approach for mutant β-catenin proteins
--------------------------------------------------------

β-Catenin protein has been a prime target for anti-cancer drug development, but some limitations may suspend successful drug development. In most cases, wild-type β-catenin protein have been utilized as a target protein and Wnt signaling activated transcription is used as a screening read-out ([@b12-molce-42-1-8]; [@b37-molce-42-1-8]; [@b56-molce-42-1-8]). As a novel strategy, the information obtained for mutant β-catenin can be implemented for mutant-specific anti-cancer therapeutics, as utilized for mutant p53 proteins ([@b6-molce-42-1-8]; [@b36-molce-42-1-8]). Large-scale clinical analysis could provide important information on the functions of cancer-related proteins and cancer signaling, as shown here ([@b29-molce-42-1-8]). Therefore, future research should be directed toward a precision oncology strategy by identifying the molecular signature of cancer-related genes and exploiting cancer genome databases ([@b74-molce-42-1-8]).
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![A schematic diagram of the Wnt signaling pathway\
(A) Wnt-off. In the absence of Wnt stimulation, β-catenin is phosphorylated by CK1α and GSK3β followed by ubiquitin-proteasome mediated proteolysis. (B) Wnt-on. Upon Wnt stimulation, the destruction complex is not functional, so the β-catenin protein is translocated into the nucleus and acts as a transcriptional co-activator to regulate oncogenic target genes. APC, Adenomatous polyposis; DVL, Disheveled.](molce-42-1-8f1){#f1-molce-42-1-8}

![The alteration frequency of CTNNB1 and APC across cancer types\
Data obtained from the MSK-IMPACT pan-cancer study on cBioportal ([www.cbioportal.org](www.cbioportal.org)).](molce-42-1-8f2){#f2-molce-42-1-8}

![Diagram of β-catenin protein domains and hotspot mutations\
(A) A schematic diagram of the β-catenin protein and mRNA. UTR, untranslated region; CDS, coding sequence; ATG, translation start codon; TAA, translation stop codon. (B) Exon 3 hotspot mutations of *CTNNB1* are marked on the lollipop plot downloaded from the MSK-IMPACT pan-cancer study on cBioportal. Deep deletions near Exon 3 of *CTNNB1* pre-mRNA are indicated as red lines. Deletion data were obtained from metastatic colorectal cancer study (MSK) on cBioportal.](molce-42-1-8f3){#f3-molce-42-1-8}

![Proposed model for the role of mutant β-catenin proteins in distinct complexes\
The green indicates wild-type β-catenin protein and the pink indicates exon 3-mutated β-catenin proteins. In addition to the adhesion, destruction and transcription complexes with the indicated proteins, additional unknown protein complexes are likely to be formed by the mutant β-catenin proteins.](molce-42-1-8f4){#f4-molce-42-1-8}

###### 

The alteration frequency of CTNNB1 in endometrial, liver, and colorectal cancer

  Cancer type                                                Sequencing data source                                   No. Sequenced   No. Alteration (%)   No. Exon3-mut (%)     Reference
  ---------------------------------------------------------- -------------------------------------------------------- --------------- -------------------- --------------------- ---------------------
  Endometrial cancer                                         Endometrial Cancer (MSK, 2018)                           187             27 (14.4)            25 (13.4)             [@b64-molce-42-1-8]
  Uterine Corpus Endometrial Carcinoma (TCGA, Nature 2013)   240                                                      71 (29.6)       63 (26.3)            [@b8-molce-42-1-8]    
  Uterine Carcinosarcoma (TCGA, PanCancer Atlas)             56                                                       1 (1.8)         0 (0.0)              [@b9-molce-42-1-8]    
  Uterine Clear Cell Carcinoma (NIH, Cancer 2017)            16                                                       0 (0.0)         0 (0.0)              [@b40-molce-42-1-8]   
  Liver cancer                                               Liver Hepatocellular Carcinoma (TCGA, PanCancer Atlas)   353             95 (26.9)            78 (22.1)             [@b9-molce-42-1-8]
  Liver Hepatocellular Carcinoma (AMC, Hepatology 2014)      231                                                      53 (22.9)       46 (19.9)            [@b3-molce-42-1-8]    
  Liver Hepatocellular Carcinoma (RIKEN, Nat Genet 2012)     25                                                       3 (12.0)        3 (12.0)             [@b15-molce-42-1-8]   
  Hepatocellular Carcinomas (Inserm, Nat Genet 2015)         243                                                      87 (35.8)       76 (31.3)            [@b61-molce-42-1-8]   
  Hepatocellular Adenoma (Inserm, Cancer Cell 2014)          30                                                       13 (43.3)       11 (36.7)            [@b54-molce-42-1-8]   
  Colorectal cancer                                          Colorectal Adenocarcinoma (TCGA, Nature 2012)            212             11 (5.2)             1 (0.5)               [@b7-molce-42-1-8]
  Colorectal Adenocarcinoma (Genentech, Nature 2012)         72                                                       5 (6.9)         2 (2.8)              [@b62-molce-42-1-8]   
  Colorectal Adenocarcinoma (DFCI, Cell Reports 2016)        619                                                      31 (5.0)        8 (1.3)              [@b17-molce-42-1-8]   
  Metastatic colorectal cancer (MSK, Cancer Cell 2018)       1099                                                     84 (7.6)        19 (1.7)             [@b73-molce-42-1-8]   
  Colon Adenocarcinoma (TCGA, PanCancer Atlas)               389                                                      27 (6.9)        15 (3.9)             [@b9-molce-42-1-8]    
  Rectum Adenocarcinoma (TCGA, PanCancer Atlas)              137                                                      8 (5.8)         0 (0.0)              [@b9-molce-42-1-8]    

Data obtained from the listed cancer studies on cBioportal ([www.cbioportal.org](www.cbioportal.org))

###### 

Status of mutations in cancer cell lines harboring activating mutations of CTNNB1

  Cancer type          Cell Line   Mutations                                                                                                                                          
  -------------------- ----------- --------------------------------------------------------- ----------------------- -------------------------------------------------------- ------- -------
  Colorectal cancer    SW48        S33Y                                                      R2714C                                                                                   
                       CCK81       T41A                                                      Y159C                   P278H                                                    S273N   
                       SNU407      T41A                                                                                                                                       R726C   G12D
                       HCT116      S45del                                                                                                                                             G13D
                       LS180       S45F                                                      R1788C                                                                           D211G   G12D
  Gastric cancer       KE39        D32N                                                                              V272L                                                            
                       AGS         G34E                                                                                                                                               G12D
                       SNU719      G34V                                                                                                                                               
                       OCUM1       S45C                                                                                                                                               
  Endometrial cancer   HEC265      D32V, X561_splice                                         P1233L                                                                                   
                       HEC6        D32V                                                                                                                                               V160A
                       HEC108      S37P, D207G                                               S678G, A2388V, T2514I   P151H                                                            
                       JHUEM2      S37C                                                                                                                                               
                       SNGM        S37P                                                      A2V                                                                                      G12V
  Lung cancer          MORCPR      S33L                                                      P865L, A2122dup         P152Rfs[\*](#tfn4-molce-42-1-8){ref-type="table-fn"}18           G13C
                       SW1573      S33F                                                                                                                                               G12C
                       LXF289      T41A                                                                              R248W                                                            
                       HCC15       S45F, Y670[\*](#tfn4-molce-42-1-8){ref-type="table-fn"}   D2796G                  D259V                                                            
  Liver cancer         HUH6        G34V                                                                              N239D, A159D                                                     
                       SNU398      S37C                                                                                                                                               
  Melanoma             SKMEL1      S33C                                                                                                                                       V600E   
                       COLO783     S45del                                                                            P27L                                                     V600E   

Mutation data obtained from Cancer Cell Line Encyclopedia (Novartis/Broad, Nature, 2012) on cBioportal ([www.cbioportal.org](www.cbioportal.org)).

Abbreviation: del, deletion; dup, duplication; fs, frame shift; splice, splice site mutation;

stop codon
